Joseph Varon is a Respiratory physician. OpenAlex indexes 1,031 publications with 12,147 citations (h-index 52); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Pulmonary Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2219 Dorrington St
Houston, TX 770303209
Telephone
713-669-1670Registry record last updated 10 May 2012.
Clinical trials
- Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department
Sponsor: The Cleveland Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Electromed, Inc.Program year20252 payments
- Insmed, Inc.Program year20259 payments
- GlaxoSmithKline, LLC.Program year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
33.6%Corticosteroid24.3%Trelegy Ellipta59%Breztri Aerosphere42%Part D≥15 patientsbeta2-Adrenergic Agonist6.9%Albuterol Sulfate Hfa57%Airsupra43%Part D<11 patients+ 1 more class in this area
Nervous system
17.9%Benzodiazepine5.8%Clonazepam100%Part D<11 patientsSSRI4.5%Paroxetine Hcl50%Sertraline Hcl50%Part D<11 patients+ 2 more classes in this area
Cardiovascular
14.2%Calcium channel blocker12%Amlodipine Besylate100%Part D≥13 patientsBeta blocker2.2%Metoprolol Succinate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
American Journal of Therapeutics
2021 - A scoping review of the pathophysiology of COVID-19
International Journal of Immunopathology and Pharmacology
2021 - MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale
Expert Review of Anti-infective Therapy
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”